Australia
# |
Name |
EBT Margin |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
57.47%
|
June 30, 2024 | USD 7.32 | 6.16% |
|
Australia |
|
2 |
22.97%
|
June 30, 2024 | USD 173.13 | 0.11% |
|
Australia |
|
3 |
7.57%
|
June 30, 2024 | USD 2.01 | -0.68% |
|
Australia |
|
4 |
5.27%
|
June 30, 2024 | USD 2.14 | 0.82% |
|
Australia |
|
5 |
1.66%
|
June 30, 2024 | USD 1.33 | 6.17% |
|
Australia |
|
6 |
0.62%
|
Dec. 31, 2023 | USD 15.47 | 4.25% |
|
Australia |
|
7 |
-20.07%
|
June 30, 2024 | USD 0.62 | -2.68% |
|
Australia |
|
8 |
-141.49%
|
June 30, 2024 | USD 2.00 | 1.52% |
|
Australia |
|
9 |
-252.36%
|
June 30, 2024 | USD 0.74 | -1.40% |
|
Australia |
|
10 |
-330.99%
|
June 30, 2024 | USD 3.66 | 3.57% |
|
Australia |
|
11 |
-365.26%
|
June 30, 2024 | USD 2.37 | 1.84% |
|
Australia |
|
12 |
-474.65%
|
June 30, 2024 | USD 3.31 | -4.06% |
|
Australia |
|
13 |
-1,111.87%
|
June 30, 2024 | USD 1.93 | -0.52% |
|
Australia |
|
14 |
-1,171.97%
|
June 30, 2024 | USD 1.53 | 1.32% |
|
Australia |
|
15 |
-1,493.51%
|
June 30, 2024 | USD 1.58 | -2.06% |
|
Australia |
|
16 |
-1,680.35%
|
Dec. 31, 2023 | USD 5.88 | 0.14% |
|
Australia |
|
17 |
-184,215.67%
|
June 30, 2024 | USD 3.82 | 6.70% |
|
Australia |
The Biotechnology company in Australia with the highest EBT Margin is Clinuvel Pharmaceuticals Limited (ASX: CUV.AX) at 57.47%.
The Biotechnology company in Australia with the lowest EBT Margin is Opthea Limited (NasdaqGS: OPT) at -184,215.67%.
The top 10 Biotechnology companies in Australia by EBT Margin are Clinuvel Pharmaceuticals Limited, CSL Limited, Nanosonics Limited, Australian Clinical Labs Limited, PolyNovo Limited, Telix Pharmaceuticals Limited, Trajan Group Holdings Limited, Immuron Limited, PYC Therapeutics Limited and Silex Systems Limited.
The bottom 10 Biotechnology companies in Australia by EBT Margin are Opthea Limited, Anteris Technologies Ltd, Mesoblast Limited, Kazia Therapeutics Limited, Immutep Limited, Alterity Therapeutics Limited, Clarity Pharmaceuticals Ltd, Silex Systems Limited, PYC Therapeutics Limited and Immuron Limited.